TriCares Topaz TTVR Clinical Studies Supported by EIB Financing 

January 20, 2026—TriCares SAS, a privately held developer of minimally invasive treatment of tricuspid regurgitation, announced it has secured up to €20 million in nondilutive financing from the European Investment Bank (EIB), the long-term lending institution of the European Union.

According to TriCares, this facility from EIB has been granted to provide flexible financing support for the company’s research, development, and innovation activities, including advancing clinical studies of its Topaz transfemoral tricuspid heart valve replacement (TTVR) system. Details of the project are published on the EIB website.

As noted in the press release, the company’s ongoing European pivotal study, TRICURE EU, is being conducted in sites across Belgium, Denmark, France, Germany, and Spain, with Switzerland to follow. A total of 80 patients will be enrolled.

Additionally, TRICURE EFS, the United States early feasibility study, will enroll 15 patients at eight sites, advised TriCares.